Torasemide: A pharmacoeconomic review of its use in chronic heart failure

PharmacoEconomics

Volumn 19, Issue 6, 2001, Pages 679-703

  Young, M ^a   Plosker, G L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Congestive heart failure; Cost effectiveness; Cost of illness; Diuretic; Pharmacoeconomics; Quality of life; Therapeutic use; Torasemide

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIAC GLYCOSIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; INOTROPIC AGENT; LOOP DIURETIC AGENT; SPIRONOLACTONE; TORASEMIDE; VASODILATOR AGENT;

ABSENTEEISM; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DEVELOPED COUNTRY; DIURETIC THERAPY; DRUG EFFICACY; DRUG INDICATION; EDEMA; FEMALE; FUNCTIONAL ASSESSMENT; HEART FAILURE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPERTENSION; KIDNEY FAILURE; LIVER CIRRHOSIS; LUNG CONGESTION; MALE; MANAGED CARE; MONEY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RETROSPECTIVE STUDY; REVIEW;

EID: 0035006070     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200119060-00006     Document Type: Review

References (88)

1. ABC of heart failure: History and epidemiology
2. Heart failure
3. Consensus recommendations for the management of chronic heart failure
4. The heart failure epidemic: Exactly how big is it?
5. Evolving trends in the epidemiologic factors of heart failure: Rationale for preventive strategies and comprehensive disease management
6. Heart failure in primary care: A striking difference between genders
7. Prevalence of heart failure and left ventricular dysfunction in the general population: The Rotterdam study
8. Cost-effectiveness analysis in clinical practice: The case of heart failure
9. Is the prognosis of heart failure improving?
10. The treatment of heart failure
11. Guidelines for the evaluation and management of heart failure
12. Self-reported differences between cardiologists and heart failure specialists in the management of chronic heart failure
13. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
14. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure
15. Effects of enalapril on mortality in severe congestive heart failure: Results of the cooperative North Scandinavian enalapril survival study (CONSENSUS)
16. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial - The losartan heart failure survival study ELITE II
17. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE trial
18. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure
19. β-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy
20. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: A randomized trial
21. Effects of short-and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy
22. Carvedilol improves left ventricular function and symptoms in chronic heart failure: A double-blind randomized study
23. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure
24. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy
25. A randomized trial of β-blockade in heart failure: The cardiac insufficiency bisoprolol study (CIBIS)
26. Safety and efficacy of carvedilol in severe heart failure
27. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure
28. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease
29. The cardiac insufficiency bisoprolol study (CIBIS-II): A randomised trial
30. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF)
31. Inappropriate use of digoxin in the elderly: How widespread is the problem and how can it be solved?
32. The effect of spironolactone on morbidity and mortality in patients with severe heart failure
33. The effect of digoxin on mortality and morbidity in patients with heart failure
34. Epidemiology, aetiology, and prognosis of heart failure
35. The health care costs of heart failure in Sweden
36. The pharmacoeconomics of ACE inhibitors in chronic heart failure
37. Effects of ACE inhibitors on heart failure in The Netherlands: A pharmacoeconomic model
38. Costs associated with symptomatic systolic heart failure
39. Health economic consequences of the pharmacological treatment of heart failure
40. Heart failure: A decision analysis of New Zealand data using the published results of the SOLVD treatment trial
41. Use of medical resources and quality of life of patients with chronic heart failure: A prospective survey in a large Italian community hospital
42. Predictors of readmission among elderly survivors of admission with heart failure
43. Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: The EPICAL study. Epidemiologie de l'insuffisance cardiaque avancee en lorraine
44. Effect of torasemide on pulmonary and cardiac haemodynamics after oral treatment of chronic heart failure
45. Clinical and haemodynamic effects of long-term treatment with torasemide in congestive heart failure
46. Clinical pharmacology of loop diuretics
47. Comparative pharmacodynamics of torasemide and furosemide in patients with oedema
48. Pharmacodynamics of torsemide administered as an intravenous injection and as a continuous infusion to patients with congestive heart failure
49. Benefits and risks of torasemide in congestive heart failure and essential hypertension
50. Clinical efficacy of torasemide, a new diuretic agent, in patients with acute heart failure: A double blind comparison with furosemide
51. Dose-response study of intravenous torsemide in congestive heart failure
52. Second line therapy of congestive heart failure with torasemide
53. Controlled, double-blind clinical trial on the efficacy and tolerance of torasemide in comparison with furosemide in patients with congestive heart failure - A multi-center study
54. Torasemide: A review of its pharmacological properties and therapeutic potential
55. Six-week study of torsemide in patients with congestive heart failure
56. Efficacy and safety of torasemide in patients with chronic heart failure
57. Torasemide in patients with chronic congestive heart failure. Results of a postmarketing surveillance study in the doctor's office
58. Improved prognosis of patients with chronic heart failure by an optimized diuretic therapy with the new loop diuretic torasemide
59. Comparison of therapies with torasemide or furosemide in patients with congestive heart failure from a pharmacoeconomic viewpoint
60. Economic evaluation of torasemide in congestive heart failure in Germany
61. Total and congestive heart failure - Related hospitalizations in patients treated with torasemide or furosemide
62. Effects of type of diuretic on mortality in patients with chronic congestive heart failure (CHF)
63. Torasemide: An update of its pharmacological properties and therapeutic efficacy
64. Focus on torsemide: A new, potent, high-ceiling loop diuretic
65. Acute and long term effects of loop diuretics in heart failure
66. Interaction between nonsteroidal anti-inflammatory drugs and loop diuretics: Modulation by sodium balance
67. Pharmacoeconomic comparison of loop diuretics in the treatment of congestive heart failure
68. A pharmacoeconomic assessment of torsemide in the treatment of congestive heart failure
69. Cost analysis of loop diuretics in heart failure
70. A pharmacoeconomic assessment of torsemide and furosemide in the treatment of patients with congestive heart failure
71. Determining the effectiveness of torasemide and furosemide in heart failure: Design of a randomised comparison using the regenstrief medical record system
72. Healthcare costs of patients with heart failure treated with torasemide or furosemide
73. Effectiveness of torsemide and furosemide in the treatment of CHF: Results of a prospective, randomized trial
74. Cost-effectiveness of torsemide versus furosemide in the treatment of heart failure
75. Torasemide eases the economic burden of CHF
76. Torsemide and furosemide in the treatment of the edema of heart failure: Interim results of a randomized effectiveness trial
77. Health care costs of heart failure: Results from a randomised study of patient education
78. Quality of life in heart failure, as measured by the SF-36 health status questionnaire
79. Self-management practices, quality of life, and healthcare resource utilization in patients with chronic heart failure
80. Baseline quality of life as a predictor of mortality and hospitalization in 5,025 patients with congestive heart failure. SOLVD investigations
81. Using the EUROQoL 'EQ-5D' to measure quality of life outcomes in heart failure
82. Sexual function in patients with advanced heart failure
83. The Minnesota living with heart failure questionnaire: Correlations with the clinical and hemodynamic parameters of heart failure
84. The effect of drug therapy on quality of life in heart failure
85. Diuretic therapy in elderly heart failure patients with and without left ventricular systolic dysfunction
86. Cost of hospitalizations for heart failure: Sodium retention versus other decompensating factors